It is made available under a CC-BY-NC-ND 4.0 International license .

1 Sex differences in innate anti-viral immune responses to respiratory

2 viruses

3

- 4 Eteri Regis^{1#}, Sara Fontanella^{1#}, Lijing Lin², Rebecca Howard², Sadia Haider¹, John A. Curtin³, Michael R.
- 5 Edwards¹, Magnus Rattray², Angela Simpson³, Adnan Custovic¹[†], Sebastian L. Johnston^{1*}[†]
- 6
- 7 ¹National Heart and Lung Institute, Imperial College London, United Kingdom
- ²Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, UK
- ³Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health,
- 10 Manchester Academic Health Sciences Centre, University of Manchester and University Hospital of South
- 11 Manchester NHS Foundation Trust, Manchester, UK
- 12
- 13 *To whom correspondence should be addressed: Sebastian L Johnston, Professor of Respiratory
- 14 Medicine & Allergy, National Heart and Lung Institute, Imperial College London, Norfolk Place, London
- 15 W2 1PG, United Kingdom; Tel: +44 20 7594 3764, e-mail: <u>s.johnston@imperial.ac.uk</u>

16

- 17 Classification: Biological sciences; Immunology and Inflammation.
- 18 Key words: mortality, respiratory virus, COVID-19, gender, innate immunity, interferons

19

- 20 Author Contributions:
- 21 [#]Eteri Regis and Sara Fontanella contributed equally to this article
- 22 †Adnan Custovic and Sebastian Johnston contributed equally to this article

23

It is made available under a CC-BY-NC-ND 4.0 International license .

25 Abstract

26 Males have excess morbidity and mortality from respiratory viral infections and especially so in COVID-27 19. The mechanisms explaining this excess in disease burden in males are unknown. Innate immune 28 responses are likely critical in protection against a novel virus like SARS-CoV-2. We hypothesised that 29 innate immune responses may be deficient in males relative to females. To test this we stimulated 30 peripheral blood mononuclear cells (PBMCs) from participants in a population-based birth cohort with 31 three respiratory viruses (rhinoviruses-RV-A16 and RV-A1, and respiratory syncytial virus-RSV) and two 32 viral mimics (R848 and CpG-A, to mimic responses to SARS-CoV-2). We measured interferon (IFN) and 33 IFN-induced chemokine responses and investigated sex differences in virus-induced responses. IFN-a, 34 IFN-β and IFN-γ responses to RV-A16 were deficient in males compared to females, fold-inductions being 35 1.92-fold (P<0.001), 2.04-fold (P<0.001) and 1.77-fold (P=0.003) lower in males than females, 36 respectively. Similar significant deficiencies in innate immune responses were observed in males for 37 eleven other cytokine-stimulus pairs. Responses in males were greater than those in females in only one 38 of 35 cytokine-stimulus pairs investigated. Review of healthcare records revealed that 12.1% of males but 39 only 6.6% of females were admitted to hospital with respiratory infections in the first year of life (P=0.017). 40 Impaired innate anti-viral immunity in males likely results in high morbidity and mortality from respiratory 41 viruses including COVID-19. Males may preferentially benefit from therapies that boost innate anti-viral 42 immune responses.

It is made available under a CC-BY-NC-ND 4.0 International license .

44 Significance Statement

45 Clinical outcomes including, mortality, Intensive care unit admissions and hospital admissions, during 46 COVID-19 disease are consistently and substantially worse in males than in females. The mechanisms 47 underlying this increased susceptibility to severe disease in males are not understood. We hypothesised 48 that the differential outcomes between sexes could be a consequence of deficient innate interferon 49 responses in males, and more robust innate interferon responses in females. We have investigated such 50 responses in a large population-based cohort and found that indeed males have deficient innate interferon 51 responses to viral stimuli, including stimuli that mimic SARS-CoV-2 infection, relative to females. Our 52 findings have very important treatment implications as interferons are available for clinical use with 53 immediate effect.

It is made available under a CC-BY-NC-ND 4.0 International license .

55 Introduction

56 Respiratory viral infections are a leading cause of ill health and mortality(1). This has been highlighted by 57 the immense global impact of COVID-19(2) and the enormous public health threat it poses. Males and 58 females differ in the prevalence and severity of viral infections(3). In COVID-19, risk factors for mortality 59 include older age, the presence of comorbid conditions, and male sex(4, 5). In an early report of 191 60 cases from Wuhan, China, 70% of deaths were male, while only 30% were female(5). This gender 61 imbalance has subsequently been confirmed in a large study of 44,672 COVID-19 confirmed cases in 62 China, where 63.8% of deaths were male while only 36.2% were female, and the case fatality rate for 63 males was 2.8%, while that for females was 1.7%(6). Similar mortality data are reported in Italy where 64 9390 of 13,334 (70.4%) of COVID-19 deaths in persons under 90 years of age reported by 6th April 2020 65 were male, and 3,944 (29.6%) were female(7). In the UK, the data are very similar, with males representing 65% of deaths involving COVID-19 reported by 27th March 2020, while 35% were 66 67 females(8). Intensive Care Unit (ICU) admission are also much higher for males in Lombardy, Italy, where 68 82% of 1591 ICU admissions were male(9). The ICU data are very similar in the UK, as 72.5% of 3883 confirmed COVID-19 cases admitted to ICU by the 10th April 2020 were male, and 27.5% female(10). A 69 70 recent large UK study of 20,133 patients admitted to hospital with COVID-19, reported more men were 71 admitted than women (men 60%, n=12 068; women 40%, n=8065)(11). An even larger study of primary 72 care records of 17,278,392 adults linked to 10,926 COVID-19-related deaths reported COVID-19-related 73 death was associated with: being male with a hazard ratio of 1.59(12). COVID-19 case identification in 74 population screening also reports a male preponderance, with more males than females testing positive 75 in both targeted testing (16.7% vs 11.0%) and in population screening (0.9% vs 0.6%)(13).

The mechanisms explaining excess COVID-19 mortality, ICU and hospital admissions and case
identification in males are unknown(14). Understanding how sexes differ in their responses to respiratory
viruses is critically important for the development of treatment and preventative strategies, which may
differ for males and females. Innate immune responses, mediated by anti-viral interferon (IFN) production
by virus-infected cells will be critical in protection against SARS-CoV-2, a new virus that humans have
never previously encountered. We have previously reported that deficient IFN-α(15), IFN-β(15, 16) and

It is made available under a CC-BY-NC-ND 4.0 International license .

82	IFN-γ(17, 18) production by	virus-infected	cells from	people with	asthma is	implicated	in their i	ncreased
----	--------------	-----------------	----------------	------------	-------------	-----------	------------	------------	----------

- 83 susceptibility to respiratory virus infections(19). However, little is known about the variation within the
- 84 human immune system in relation to the patterns of response to viruses at a population level. We
- 85 hypothesised that the adverse outcomes for males reported in COVID-19 may be related to deficient
- 86 innate immune responses to viruses in males relative to females. To investigate this, we stimulated
- 87 peripheral blood mononuclear cells (PBMCs) from male and female participants in a population-based
- 88 birth cohort with three common respiratory viruses and two viral mimics (R848 and CpG-A, to mimic
- 89 responses to SARS-CoV-2) and measured IFN and IFN-induced chemokine responses in supernatants.

It is made available under a CC-BY-NC-ND 4.0 International license .

91 Results

92 Participant flow and demographic data

Of 751 participants who attended follow-up at age 16 years, 361 provided blood samples. After quality
control (Supplementary Appendix), we excluded data for 16 participants. Participant flow is presented in
Fig. 1. There were no differences in demographic characteristics, environmental exposures and clinical
features between participants included in this analysis (n=345) and those who were not (n=406), either in
the whole population or stratified by sex (Table S1).

98 The demographic and clinical characteristics of the 345 subjects included in this analysis are shown in

99 Table 1. There were no significant differences between sexes in birth weight, relevant environmental

100 exposures (including position in sibship, pet ownership and tobacco smoke exposure) or common

101 respiratory diseases, such as wheezing and asthma. No significant differences were observed in cell

102 viability between sexes (Fig. S1).

103 Induction of IFNs and IFN-induced chemokines in PBMCs in response to viral stimuli

There was a significant induction of all IFNs and IFN-induced chemokines in response to all viral stimuli compared to medium control (Figures 2 and S2). Cytokine responses to viral stimuli were not normally distributed (Shapiro-Wilk test, Table S2). The most potent inducers of IFN-α were CpG-A, RSV and RV-A16, with median concentrations of 184.7pg/mL, 108.3pg/mL and 34.0pg/mL respectively compared to 0.0pg/mL in medium control (all *P*<0.001, Figure 2). RV-A1 and R848 also induced IFN-α, but to lesser degrees (Fig. 2). Induction of IFN-β followed a very similar pattern to that of IFN-α, but with lower concentrations.

111 The most potent inducers of IFN-γ were R848, RV-A16 and RSV, with median concentrations of

112 102.1pg/mL, 60.7pg/mL and 35.7pg/mL, respectively, compared to 0.2pg/mL in medium control (all

113 *P*<0.001, Figure 2). RV-A1 and CpG-A also induced IFN-γ, but to lesser degrees (Fig. 2).

114 The most potent inducers of the IFN-induced chemokine CXCL10/IP-10, were RV-A16, RSV and CpG-A,

115 with median concentrations of 1841.0pg/mL, 1515.2pg/mL and 1343.4pg/mL respectively, compared to

medRxiv preprint doi: https://doi.org/10.1101/2020.09.18.20195784; this version posted September 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

130.6pg/mL in medium control samples (all *P*<0.001, Figure 2). RV-A1 and R848 also induced CXCL-

- 117 10/IP-10, but to lesser degrees.
- 118 The IFN-induced chemokines CCL2/MCP1, CCL4/MIP-1β and CCL13/MCP4 were also all induced by all
- viral stimuli, CCL2/MCP1 and CCL4/MIP-1β most potently by R848 and CCL13/MCP4 most potently by
- 120 RV-A1 (Fig. S2).
- 121 Differences between males and females in IFN and IFN-induced chemokine induction
- 122 Results of the comparisons between sexes are presented in Table 2. The trend across all viral stimuli and
- 123 responses was remarkably consistent, as almost all of the IFNs and IFN-induced chemokines had higher
- 124 levels of induction in females compared to males: out of 35 stimulus-cytokine pairs, females exhibited
- higher induction than males in 32 cases (Table 2).
- 126 The induction of IFN- α was significantly higher in females than in males for all five viral stimuli (with *P*-
- values ranging from <0.001 to 0.018, Table 2). After adjustment for multiple testing, these differences
- remained statistically significant for RV-A16, RV-A1 and R848 (P=0.001, 0.041 and 0.002 respectively),
- and marginal for RSV and CpG-A (P=0.055 and 0.051 respectively, Table 2). The magnitude of the
- 130 differences observed for IFN- α ranged from a 1.34-fold (34%) greater induction of IFN- α in females than
- in males for RSV, to a 2.06-fold (106%) greater induction for R848.
- 132 The individual responses of each IFN and of CXCL10/IP-10 to RV-A16 stimulation are depicted in Fig. 3
- A-D, with induction in females significantly greater than that in males for IFN- α at 1.92-fold (92%) greater
- 134 (P<0.001), IFN-β at 2.04-fold (104%) greater (P<0.001), IFN-γ 1.77-fold (77%) (P=0.003) and CXCL10/IP-
- 135 10 1.40-fold (40%) greater (*P*=0.01).
- 136 Regarding the viral mimics R848 and CpG-A (which mimic responses to SARS-CoV-2 infection), females
- had significantly greater induction of IFN- α in response to R848 stimulation (2.06-fold, *P*<0.001), and in
- 138 response to CpG-A (1.71-fold, P=0.015) (Fig. 4 A-B), though the latter difference was marginal after
- 139 adjustment (*P*=0.051, Table 2). Females also had significantly greater induction of IFN-γ (2.01-fold,
- 140 P=0.003) and CCL13/MCP4 (1.36-fold, P=0.04) in response to CpG-A than males (Fig. 4 C-D), though
- the latter difference was marginal after adjustment (*P*=0.10, Table 2).

It is made available under a CC-BY-NC-ND 4.0 International license .

Stimulation with RV-A1 also resulted in significantly greater induction in females than in males for IFN- α (Fig. S3A, 1.55-fold, *P*=0.011), CXCL10/IP-10 (Figure S3B, 1.23-fold, *P*=0.041, though this difference was marginal after adjustment [*P*=0.10, Table 2]), CCL4/MIP-1 β (Fig. S3C, 1.16-fold, *P*=0.01) and CCL13/MCP4 (Fig. S3D, 1.61-fold, *P*=0.002), as did stimulation with RSV (Fig. S3 E-F) for IFN- α (*P*=0.018) and CCL13/MCP4 (*P*=0.019). These latter two differences were marginal after adjustment (both *P*=0.055, Table 2).

148 Since adverse clinical outcomes in viral infections are likely in those individuals with the weakest innate 149 anti-viral responses, we examined proportions of males and females whose innate anti-viral responses 150 were below certain lower thresholds. We restricted this analysis to IFN- α and low thresholds were defined 151 as the 15th, 20th and 25th percentile of the response determined from the entire population. Results are 152 shown in Fig. 5 and S4. Proportions of males having IFN-α responses to RV-A16, RSV and R848 below 153 each threshold were significantly higher compared to the proportion of females (Fig. 5). Similar trends 154 were observed for response of IFN- α to RV-A1, and CpG-A (Fig. S4), but these did not reach statistical 155 significance.

156 Differences in early-life severe LRTIs between males and females

157 Having observed diminished innate immune responses to viral stimuli in males, and greater proportions of 158 males with weak innate immune responses, we investigated whether frequencies of early-life LRTIs were 159 also different between sexes in our cohort. We focussed on early life, as this is when innate immune 160 responses will be most important, as the very young will have had little opportunity to develop memory 161 responses. Results are presented in Table S3. Among participants attending follow up at age 16 years 162 who had primary care records available for inspection (n=651), 12.1% of males and 6.6% of females were 163 admitted to hospital with LRTI in the first year of life (P=0.017). In the second year of life, 6.1% of males 164 but only 0.75% of females were admitted to hospital with LRTI (P < 0.001). We observed a similar trend 165 for RSV-positive bronchiolitis, with 4.32% of males hospitalised, compared to 1.64% of females, but the 166 difference between the sexes did not reach formal statistical significance (P=0.067).

It is made available under a CC-BY-NC-ND 4.0 International license .

168 Discussion

169 We hypothesised that the adverse outcomes for males reported in virus infections and especially in 170 SARS-CoV-2 infections, including substantially increased COVID-19-related mortality, ICU admissions, 171 hospital admissions and case identification, may be related to deficient innate immune responses in 172 males relative to females, resulting in increased disease severity in males. Our analysis of induction of 173 three IFNs and four IFN-induced chemokines by five respiratory viruses/viral stimuli in PBMCs sampled 174 from participants in a population-based birth cohort study demonstrated that responses in females were 175 substantially greater than those in males in 32 of 35 cytokine-stimulus pairs. Of these, differences in 14 176 cytokine-stimulus pairs were statistically significant, of which 9 remained significant after adjustment for 177 multiple testing, all showing increased responses in females. These statistically significant cytokine-178 stimulus pairs included IFN-α induction in response to each viral stimulus, IFN-β induction in response to 179 RV-A16 and IFN-y induction in response to RV-A16 and CpG-A. IFN-α and IFN-β are type I IFNs that are critical mediators of innate anti-viral immune responses, inducing 180 181 apoptosis of virus-infected cells and inducing over 300 IFN-stimulated genes, many of which have a 182 variety of direct anti-viral activities(20). Through these combined activities, type I IFNs can abort virus 183 replication in virus-infected cells(16). 184 IFN-y is the only type II IFN, and it also is very important in promoting innate immune responses 185 principally by activating natural killer (NK) cells which are important in innate immune defense against 186 virus infections, by rapid killing of virus-infected cells(21). IFN-y also primes other immune cells such as 187 macrophages, to release anti-viral cytokines(22) and to phagocytose infected cells(21). IFN-y has been

shown to suppress mouse coronavirus replication, though this was dependent, in part, on induction of
type I IFN secretion(23).

Type I and II IFNs also cooperate and work together to activate macrophages, NK cells, dendritic cells
and T cells by enhancing cell activation, antigen presentation, cell trafficking, cell differentiation and
proliferation, resulting in markedly enhanced innate and acquired antiviral immune effector function(24).
Thus, deficiency in either or both of these IFN types would be expected to markedly increase severity of
virus-induced illnesses. We have previously described deficiency in IFN-α(15), IFN-β(15, 16) and IFN-

It is made available under a CC-BY-NC-ND 4.0 International license .

195 γ(17, 18) in patients with asthma and have reported that patients with asthma have increased
196 susceptibility to respiratory virus infections(19). In addition, recent reports indicate that deficiencies in IFN
197 responses are linked to increased susceptibility to virus-induced exacerbations of chronic obstructive
198 pulmonary disease(25-28). These data therefore support the biological and clinical relevance of our
199 findings.

200 The deficiencies we observed in IFN responses in males are reflected in a significantly increased 201 incidence of severe LRTIs requiring hospital admissions in the first and second years of life, as well as 202 with a trend for increased incidence of RSV-proven bronchiolitis, a disease with a peak incidence at 4.5 203 months of age(29). We focused on severe LRTIs requiring hospital admissions in early life, as these are 204 almost exclusively viral in aetiology. The first 2 years of life is a time of life during which innate immune 205 responses will be most important, as infants and toddlers will have had very little experience of viral RTIs 206 and will therefore have little memory/acquired immunity. The fact that we find females produce 207 approximately twice the concentrations of IFN- α and IFN- β in response to RV-A16 and of IFN- α in 208 response to R848, 55% more IFN- α in response to RV-A1 and 71% and 52% more IFN- α and IFN- β in 209 response to CpG-A, than do males, and females have ~half the number of LRTIs requiring hospital 210 admission in the first year of life, 88% fewer in the second year of life and 62% fewer admissions with 211 RSV-positive bronchiolitis also lends credence to the biological and clinical relevance of our findings in 212 relation to diseases where innate immune responses will be vitally important in protection against adverse 213 outcomes.

SARS-CoV-2 is a virus completely new to mankind, it is therefore even more important to have as strong an innate immune response to this virus as possible, to reduce the likelihood of adverse outcomes. The marked reductions in type I IFN responses to viral stimuli reported herein in males relative to females, with the relationships discussed above with virus-induced exacerbations of lung disease(15-18, 25-28), and with severe viral LRTIs in infants in our cohort, make it almost certain that the deficient IFN responses we report in males will be at least in part responsible for the adverse outcomes to SARS-CoV-2 infection currently being reported in COVID-19 in males(2, 4-10, 12, 13).

It is made available under a CC-BY-NC-ND 4.0 International license .

221 A very recent study by Takahashi et al studied sex differences in immune responses during COVID-19 222 disease in hospitalised patients and claimed that these differences underlie sex differences in COVID-19 223 disease outcomes(30). This study reported female patients mounted significantly more robust T cell 224 activation than male patients during SARS-CoV-2 infection. They also found that a poor T cell response 225 was associated with worse disease outcome in male patients. This study also reported significantly 226 increased plasma concentrations of IL-8 and IL-18 and numbers of peripheral blood non-classical 227 monocytes in males, with trends to increased SARS-CoV-2 virus load (of magnitude 1-2 Log₁₀ copies/mL, 228 noting that virus load was only measured in the upper respiratory tract and not in the lung) and plasma 229 CXCL-10 concentrations in males. As robust innate interferon responses are well known to drive robust T 230 cell responses during viral infections(24), and deficient innate interferon responses studied ex vivo pre-231 infection are known to relate to increased virus load, increased inflammatory outcomes and worse clinical 232 outcomes upon subsequent in vivo respiratory virus infection(31), we suggest all the differential outcomes 233 between sexes identified by Takahashi et al would be a consequence of the deficient innate interferon 234 responses in males, and more robust innate interferon responses in females, that we report herein.

235 Our study has strengths and limitations. Strengths include the population-based cohort design, so our participants should be representative of the general population, the fact that illness ascertainment was 236 237 carried out by personal inspection of primary care records to maximise accuracy, that PBMCs were 238 stimulated/infected with the most common respiratory viruses and with ligands of TLRs that are 239 representative of RNA respiratory viruses such as SARS-CoV-2, and that infections/stimulations were 240 carried out using a single batch of each virus/stimulus and conducted by a single highly experienced 241 individual, so any variability in response will be participant-related and not a result of technical variability. 242 Limitations include that PBMCs were not directly infected/stimulated with SARS-CoV-2. This was not 243 possible as our participants' PBMCs were infected/stimulated before SARS-CoV-2 existed as a human 244 pathogen. However, we did study ligands (R848 and CpG-A) to the endosomal expressed TLRs 7/8/9. 245 which are clearly engaged by positive strand RNA viruses such SARS-CoV-2, which require endosomal 246 processing as part of viral entry into cells(32). Furthermore, consistency of findings across all viral stimuli 247 and responses suggests that our findings should apply to all respiratory viruses including SARS-CoV-2.

It is made available under a CC-BY-NC-ND 4.0 International license .

We were not able to assess the importance of induction of the type III IFNs, IFN-λs 1-3, which are very
important in innate antiviral responses against respiratory viruses(31, 33-35), as the type III IFNs were not
significantly induced by any infection/stimulus in the PBMCs that we studied (data available on request).
This is likely because respiratory epithelial cells are the main source of type III IFNs, and the cells within
PBMCs that are capable of producing type III IFNs when studied fresh(35) likely succumbed as a result of
freeze/thawing.

Our findings have important therapeutic implications. IFN- α and IFN- β have both been shown to inhibit replication of SARS-CoV-2(36, 37). A very recent report indicates that early subcutaneous IFN- β administered up to three times weekly (with ribavirin) in the first seven days after diagnosis of COVID-19 was associated with faster virus clearance and clinical improvement and with shorter hospital stays(38). It is likely that most of this clinical benefit resulted from IFN- β rather than ribavirin(39), but ongoing clinical trials (more than 20 trials investigating IFN- α or IFN- β in COVID-19 are currently registered on clinical trial registries) will determine whether and to what degree type I IFN therapies are effective.

261 Since IFN production by virus-infected respiratory cells is likely critical to innate anti-viral immunity against 262 SARS-CoV, therapeutic use of agents that boost innate IFN induction by virus infections may be 263 efficacious in treatment of COVID-19. We reported 10 years ago that azithromycin doubles IFN-β and 264 IFN- λ production from virus-infected human bronchial epithelial cells *in vitro*(40). Erythromycin and 265 telithromycin did not(40). Innate IFN-induction by azithromycin in virus-infected human lung cells has 266 been confirmed in three subsequent studies(41-43), one of which confirmed this property was variable 267 among 225 novel macrolides studied, as some macrolides induced innate IFNs (up to ~5-fold), while 268 others did not(43). Thus this innate IFN-inducing property is not a property of all macrolides, but is 269 reproducibly a property of azithromycin(40-43). This is supported by a recent report that among 1,520 270 clinically approved compounds from a chemical library screened for anti-viral activity against SARS-CoV-2, only two had clear dose-responsive replication-inhibition curves with identified EC₅₀ concentrations in 271 272 the 1-10µM range. These two compounds were azithromycin and hydroxychloroguine, and they also had EC₉₀ concentrations of ~10µM and ~15µM respectively, with azithromycin achieving ~100% inhibition of 273 274 SARS-CoV-2 replication at ~15µM(44). Azithromycin treatment of COVID-19 patients (especially early in

It is made available under a CC-BY-NC-ND 4.0 International license .

275 the disease course when patients progress from mild to moderate disease severity) in order to boost IFN 276 production by respiratory epithelial cells when infected with SARS-CoV-2, may therefore be effective, 277 especially in males who demonstrably have deficient innate IFN responses when compared to females. 278 This deduction is indirectly supported by high-quality randomised, double-blind, placebo-controlled clinical 279 trial evidence that azithromycin is effective in preventing progression to severe lower respiratory tract 280 illnesses (which are initiated by viral infections) in preschool children(45) and in prevention of asthma 281 exacerbations (the great majority of which are caused by respiratory viruses) in uncontrolled 282 moderate/severe asthma(46). Ongoing studies (more than 50 clinical trials investigating azithromycin in 283 COVID-19 are currently on trial registries) will determine the effectiveness of azithromycin, and we would 284 suggest that post-hoc analyses include stratification by sex. 285 Our findings have important implications for prevention strategies, which are best implemented when 286 high-risk populations can be identified. Respiratory viruses, including SARS-CoV-2, are initially 287 encountered by the nasal epithelium where infection is initiated. An adequate anti-viral response can

contain the virus in the upper airway, with cold-like symptoms, and a diminished response can see the

infection spreading to the lower airways to induce severe LRTI. Our data support a preventive strategy,

290 particularly among males, which involves targeting the innate immune system with 'immune training'

agents to boost resistance to primary infection with SARS-CoV-2 and enhance the capacity to control the

intensity of airways' inflammatory responses (such as, for example, OM-85(47), which has been shown to

293 effectively and safely reduce winter hospitalizations in COPD(48), severe bronchitis among residents in

care-homes for elderly(49), and LRTIs in children(50)). Effective prophylactic therapy will be crucially

important while we wait for a vaccine.

Our findings also have important implications for a hotly debated topic, namely whether "man flu" actually
 exists or not(51). Here we provide a biological basis to explain why males would be expected to suffer
 more than females when infected by respiratory viruses.

In conclusion, high morbidity and mortality from respiratory viruses including COVID-19 in males is likely
 explained by impaired innate anti-viral immune in males compared to females. Males may preferentially

It is made available under a CC-BY-NC-ND 4.0 International license .

- 301 benefit from therapies that boost innate anti-viral immune responses to viruses, both for treatment and
- 302 prevention.

It is made available under a CC-BY-NC-ND 4.0 International license .

303 Materials and Methods

304 Detailed methods are presented in the Supplementary Appendix.

305 Study design, setting, participants and data sources

306 The study subjects were participants in the Manchester Asthma and Allergy Study, a population-based

307 birth cohort study(52). The study was approved by the research ethics committee; we obtained written

308 informed consent. PBMCs were collected from subjects at age 16 years and cryopreserved. We used

309 male or female sex as assigned at birth.

310 Cell stimulations and cytokine measurement

- The PBMCs were thawed on the day of stimulation, counted and had viability checked as described(53,
- 54). Cells were distributed in 96-well round bottom plates at 2^{10^5} cells/well and were stimulated with two
- rhinoviruses (RVs), RV-A16 and RV-A1, and respiratory syncytial virus (RSV). We also used two viral
- 314 mimics (which mimic infection with SARS-CoV-2), the Toll-like receptor (TLR)-7/8 ligand resiquimod
- 315 (R848) and the TLR-9 ligand class A CpG oligonucleotide (CpG-A), both at 1µM concentrations
- 316 (Invivogen). Concentrations of IFN- α , IFN- β , IFN- γ and four IFN-induced chemokines CXCL10/IP-10,
- 317 CCL2/MCP1, CCL4/MIP-1β and CCL13/MCP4 were measured in supernatants 24h post-stimulation,
- 318 using the Meso Scale Discovery® kits as previously described(53, 54).

319 Clinical outcomes: Lower respiratory tract infections (LRTI)

- 320 We extracted data on severe LRTIs requiring hospital admissions in the first and second year of life from
- 321 electronic and paper-based primary care medical records; age in days at the time of each event was
- documented to provide an accurate account of each episode(54).

323 Statistical analysis

- 324 *Quality control:* Prior to analyses, data were pre-processed according to the pipeline described in our 325 previous study(53), to exclude samples with low viability and/or no response of any cytokine to any stimulus.
- 326 *Analysis:* We expressed the induction of IFNs and IFN-induced chemokines as raw values (in pg/mL) and
- 327 fold-induction over medium controls. The data were summarised as median and interquartile range (IQR).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 328 Univariate comparisons between groups were performed using the Wilcoxon rank sum test (2-tailed).
- 329 Benjamini-Hochberg correction was applied to account for multiple testing(55). Proportions of males and
- females with IFN responses to viral stimuli below the 15th, 20th and 25th percentiles of the entire
- population were compared using chi-squared tests. Associations with P<0.05 were considered significant.

332 Data availability

- 333 The data that support the findings of this study are available from the corresponding author upon
- 334 reasonable request.

It is made available under a CC-BY-NC-ND 4.0 International license .

336 Acknowledgments:

337 Funding: MRC grants MR/L012693/1, MR/K002449/2 and MR/S025340/1. SLJ is the Asthma UK Clinical

338 Chair (grant CH11SJ) and a National Institute of Health Research (NIHR) Emeritus Senior Investigator

- and is funded in part by European Research Council Advanced Grant 788575. This research was
- 340 supported by the NIHR Imperial and Manchester Biomedical Research Centres (BRCs). The views
- 341 expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health
- 342 and Social Care.
- 343 **Author contributions:** All authors contributed to the writing of the manuscript and have approved the

final version for publication. E.R., S.F., L.L., R.H., J.C., M.R. and M.E. performed the data analyses and

E.R., S.F., graph and table production. E.R. performed all cell infections/stimulations and all cytokine

346 measurements. S.H. performed primary care record inspection. A.S. coordinated the clinical study, A.C.

and S.J. lead the study design, supervision and interpretation of the studies.

A.S., A.C. and S.J. are responsible for the overall content as guarantors. The guarantors accept full

responsibility for the work, the conduct of the study, had access to the data, and controlled the decision to

350 publish. The corresponding author attests that all listed authors meet authorship criteria and that no

351 others meeting the criteria have been omitted.

352 **Competing interests:** Dr. Johnston reports personal fees from Virtus Respiratory Research, personal

353 fees from Myelo Therapeutics GmbH, personal fees from Concert Pharmaceuticals, personal fees from

354 Bayer, personal fees from Synairgen, personal fees from Novartis, personal fees from Boehringer

Ingelheim, personal fees from Chiesi, personal fees from Gerson Lehrman Group, personal fees from

resTORbio, personal fees from Bioforce, personal fees from Materia Medical Holdings, personal fees from

357 PrepBio Pharma, personal fees from Pulmotect, personal fees from Virion Health, personal fees from

358 Lallemand Pharma, personal fees from AstraZeneca, outside the submitted work; In addition, Dr.

Johnston has a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory

- diseases. UK patent application No. GB 0405634.7, 12 March 2004. with royalties paid, a patent Wark
- 361 PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus Therapy for Respiratory
- 362 Diseases. International Patent Application No. PCT/GB05/50031, 12 March 2004. with royalties paid, and

It is made available under a CC-BY-NC-ND 4.0 International license .

- 363 a patent Davies DE, Wark PA, Holgate ST, Johnston SL. Interferon Lambda therapy for the treatment of
- respiratory disease. UK patent application No.6779645.9, granted 15th August 2012. licensed.
- 365 Dr. Custovic reports personal fees from Novartis, personal fees from Thermo Fisher Scientific, personal
- 366 fees from Philips, personal fees from Sanofi, personal fees from Stallergenes Greer, outside the
- 367 submitted work.
- 368 Dr. Simpson reports grants from MRC, grants from NIHR BRC, during the conduct of the study.
- 369 Dr. Curtin reports a patent with the University of California at San Francisco, unrelated to the submitted
- 370 work.
- 371 The rest of the authors declare that they have no relevant conflicts of interest.

It is made available under a CC-BY-NC-ND 4.0 International license .

372 References

373 J. P. Mizgerd, Lung infection--a public health priority. *PLoS Med* **3**, e76 (2006). 1. 374 2. F. Wu et al., A new coronavirus associated with human respiratory disease in China. Nature 579, 375 265-269 (2020). 376 3. S. L. Klein, Sex influences immune responses to viruses, and efficacy of prophylaxis and 377 treatments for viral diseases. Bioessays 34, 1050-1059 (2012). 378 4. X. Li et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J 379 Allergy Clin Immunol 10.1016/j.jaci.2020.04.006 (2020). F. Zhou et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 380 5. 381 Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 (2020). 382 6. T. Novel Coronavirus Pneumonia Emergency Response Epidemiology, [The epidemiological 383 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi **41**, 145-151 (2020). 384 385 7. L. e. p. l. s. p. l. S. d. Sanità., Characteristics of COVID-19 patients dying in Italy. Report based on 386 available data on April 6th , 2020. 387 8. O. o. N. Statistics, The number of deaths involving COVID-19 for females was lower than males in 388 all age groups. (2020). 389 9. G. Grasselli et al., Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-390 CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 10.1001/jama.2020.5394 (2020). 391 10. I. c. n. a. r. c. (ICNARC), ICNARC report on COVID-19 in critical care 10 April 2020. 5 (2020). 392 11. A. B. Docherty et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC 393 WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369, 394 m1985 (2020). 395 E. J. Williamson et al., Factors associated with COVID-19-related death using OpenSAFELY. 12. 396 Nature 584, 430-436 (2020). 397 13. D. F. Gudbjartsson et al., Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med 398 10.1056/NEJMoa2006100 (2020). 399 C. Wenham, J. Smith, R. Morgan, Gender, C.-W. Group, COVID-19: the gendered impacts of the 14. 400 outbreak. Lancet 395, 846-848 (2020). 401 15. A. Sykes et al., Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar 402 lavage cells in asthmatic patients. J Allergy Clin Immunol 129, 1506-1514 e1506 (2012). 403 16. P. A. Wark et al., Asthmatic bronchial epithelial cells have a deficient innate immune response to 404 infection with rhinovirus. J Exp Med 201, 937-947 (2005). 405 17. S. D. Message et al., Rhinovirus-induced lower respiratory illness is increased in asthma and 406 related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 105, 407 13562-13567 (2008). 408 18. N. G. Papadopoulos, L. A. Stanciu, A. Papi, S. T. Holgate, S. L. Johnston, A defective type 1 409 response to rhinovirus in atopic asthma. Thorax 57, 328-332 (2002). J. M. Corne et al., Frequency, severity, and duration of rhinovirus infections in asthmatic and 410 19. 411 non-asthmatic individuals: a longitudinal cohort study. Lancet 359, 831-834 (2002). 412 20. J. W. Schoggins et al., A diverse range of gene products are effectors of the type I interferon 413 antiviral response. Nature 472, 481-485 (2011). 414 21. S. N. Waggoner et al., Roles of natural killer cells in antiviral immunity. Curr Opin Virol 16, 15-23 415 (2016).

416	22.	A. Nikonova <i>et al.</i> , M1-like macrophages are potent producers of anti-viral interferons and M1-
417		associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma
418		exacerbations. EBioMedicine 54, 102734 (2020).
419	23.	L. Whitman, H. Zhou, S. Perlman, T. E. Lane, IFN-gamma-mediated suppression of coronavirus
420		replication in glial-committed progenitor cells. Virology 384 , 209-215 (2009).
421	24.	L. Malmgaard, Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res
422		24 , 439-454 (2004).
423	25.	L. J. Finney et al., Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar
424		Macrophages in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 199, 1496-
425		1507 (2019).
426	26.	P. Mallia et al., Experimental rhinovirus infection as a human model of chronic obstructive
427		pulmonary disease exacerbation. Am J Respir Crit Care Med 183, 734-742 (2011).
428	27.	A. Singanayagam et al., Corticosteroid suppression of antiviral immunity increases bacterial
429		loads and mucus production in COPD exacerbations. Nat Commun 9, 2229 (2018).
430	28.	A. Singanayagam et al., Antiviral immunity is impaired in COPD patients with frequent
431		exacerbations. Am J Physiol Lung Cell Mol Physiol 317 , L893-L903 (2019).
432	29.	R. Thwaites <i>et al.</i> , Clinical burden of severe respiratory syncytial virus infection during the first 2
433		years of life in children born between 2000 and 2011 in Scotland. Eur J Pediatr 179, 791-799
434		(2020).
435	30.	T. Takahashi et al., Sex differences in immune responses that underlie COVID-19 disease
436		outcomes. <i>Nature</i> 10.1038/s41586-020-2700-3 (2020).
437	31.	M. Contoli et al., Role of deficient type III interferon-lambda production in asthma
438		exacerbations. Nat Med 12, 1023-1026 (2006).
439	32.	N. Yang, H. M. Shen, Targeting the Endocytic Pathway and Autophagy Process as a Novel
440		Therapeutic Strategy in COVID-19. Int J Biol Sci 16, 1724-1731 (2020).
441	33.	E. Andreakos, I. Zanoni, I. E. Galani, Lambda interferons come to light: dual function cytokines
442		mediating antiviral immunity and damage control. Curr Opin Immunol 56, 67-75 (2019).
443	34.	I. E. Galani et al., Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection
444		against Influenza Virus Infection without Compromising Host Fitness. Immunity 46, 875-890
445		e876 (2017).
446	35.	M. R. Khaitov et al., Respiratory virus induction of alpha-, beta- and lambda-interferons in
447		bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 64, 375-386 (2009).
448	36.	E. Mantlo, N. Bukreyeva, J. Maruyama, S. Paessler, C. Huang, Antiviral activities of type I
449		interferons to SARS-CoV-2 infection. Antiviral Res 179, 104811 (2020).
450	37.	U. Felgenhauer et al., Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem
451		10.1074/jbc.AC120.013788 (2020).
452	38.	I. F. Hung et al., Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
453		treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2
454		trial. <i>Lancet</i> 10.1016/S0140-6736(20)31042-4 (2020).
455	39.	S. Shalhoub, Interferon beta-1b for COVID-19. <i>Lancet</i> 10.1016/S0140-6736(20)31101-6 (2020).
456	40.	V. Gielen, S. L. Johnston, M. R. Edwards, Azithromycin induces anti-viral responses in bronchial
457		epithelial cells. <i>Eur Respir J</i> 36 , 646-654 (2010).
458	41.	M. Menzel, H. Akbarshahi, L. Bjermer, L. Uller, Azithromycin induces anti-viral effects in cultured
459		bronchial epithelial cells from COPD patients. Sci Rep 6, 28698 (2016).
460	42.	M. Menzel et al., Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in
461		experimental models of asthma exacerbation. Oncotarget 8, 31601-31611 (2017).

462	43.	J. D. Porter <i>et al.</i> , Identification of novel macrolides with antibacterial, anti-inflammatory and
463		type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother 71 , 2767-
464		2781 (2016).
465	44.	F. Touret <i>et al.</i> , In vitro screening of a FDA approved chemical library reveals
466		potential inhibitors of SARS-CoV-2 replication. 10.1101/2020.04.03.023846 %J bioRxiv,
467		2020.2004.2003.023846 (2020).
468	45.	L. B. Bacharier et al., Early Administration of Azithromycin and Prevention of Severe Lower
469		Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized
470		Clinical Trial. JAMA 314 , 2034-2044 (2015).
471	46.	P. G. Gibson et al., Effect of azithromycin on asthma exacerbations and quality of life in adults
472		with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled
473		trial. <i>Lancet</i> 390 , 659-668 (2017).
474	47.	P. Holt, D. Strickland, A. Custovic, Targeting maternal immune function during pregnancy for
475		asthma prevention in offspring: harnessing the "farm effect"? J Allergy Clin Immunol
476		10.1016/j.jaci.2020.04.008 (2020).
477	48.	J. P. Collet et al., Effects of an immunostimulating agent on acute exacerbations and
478		hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study
479		Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an
480		Immunostimulant. Am J Respir Crit Care Med 156, 1719-1724 (1997).
481	49.	B. Orcel, B. Delclaux, M. Baud, J. P. Derenne, Oral immunization with bacterial extracts for
482		protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis.
483		Eur Respir J 7 , 446-452 (1994).
484	50.	S. Esposito <i>et al.</i> , A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial
485		to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract
486		infections. <i>J Transl Med</i> 17 , 284 (2019).
487	51.	I. Iheanacho, Take it like a man: pseudodrugs for man flu. BMJ 342, d2863 (2011).
488	52.	A. Custovic et al., The National Asthma Campaign Manchester Asthma and Allergy Study. Pediatr
489		Allergy Immunol 13 , 32-37 (2002).
490	53.	A. Custovic et al., Cytokine Responses to Rhinovirus and Development of Asthma, Allergic
491		Sensitization, and Respiratory Infections during Childhood. Am J Respir Crit Care Med 197, 1265-
492		1274 (2018).
493	54.	A. Semic-Jusufagic et al., Assessing the association of early life antibiotic prescription with
494		asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-
495		based birth cohort study. Lancet Respir Med 2, 621-630 (2014).
496	55.	Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful
497		Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological)
498		57 , 289-300 (1995).

It is made available under a CC-BY-NC-ND 4.0 International license .

500 Figures and Tables



- 501
- 502 Fig. 1: Participant flow and PBMC stimulation numbers for each stimulus.
- 503

It is made available under a CC-BY-NC-ND 4.0 International license .



505

Figure 2. Patterns of PBMC cytokine induction by viral stimuli, compared to medium controls.
Data were analysed using Wilcoxon test. Each dot represents an individual participant. Box plots
represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th percentiles.
Data are presented in pg/mL. The y axis is plotted on a logarithmic scale. Significant levels: ****P*<001
compared to medium.

It is made available under a CC-BY-NC-ND 4.0 International license .







Box plots represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th percentiles. Each dot represents an individual participant. Wilcoxon test: A) P<0.001, B) P<0.001, C) P=0.003 and D) P=0.010. Data are presented as fold induction. The y axis is plotted on a logarithmic scale.

It is made available under a CC-BY-NC-ND 4.0 International license .



519

520 Figure 4: Females have significantly greater induction than males of type I and II IFNs and

521 CCL13/MCP4 in response to the viral mimics R848 and CpG-A.

Box plots represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th precentiles. Each dot represents an individual participant. Wilcoxon test: A) P<0.001, B) P=0.015, C) P=0.003 and D) P=0.040. Data are presented as fold induction. The y axis is plotted on a logarithmic

525 scale.

It is made available under a CC-BY-NC-ND 4.0 International license .



527 Figure 5: Proportions of males and females with IFN responses to RV-A16, RSV and R848 below

- 528 the 15th, 20th and 25th percentiles of the entire population.
- 529 *P*-values are derived using chi-squared tests.

It is made available under a CC-BY-NC-ND 4.0 International license .

530 Table 1: Comparison between sexes of demographic and clinical characteristics of the study

531 population.

532 Some data was lost due to individuals not attending a follow up or skipping the question

	Cytokine data (n=345)		
	Female	Male	p-value
	n (%)	n (%)	χ²
Ethnicity (Caucasian)	121/126(96.0)	204/212(96.2)	0.504
Younger siblings	112/217(51.6)	70/128(54.7)	0.581
Older siblings	62/128 (48.4)	121/215 (56.3)	0.159
Day care attendance	91/121(75.2)	153/209(73.2)	0.690
Maternal smoking (pregnancy)	9/128 (7.0)	19/212 (9.0)	0.530
Maternal smoking (current)	10/126(7.9)	29/217(13.4)	0.127
Maternal asthma	23/128 (18.0)	39/217 (18.0)	0.999
Paternal asthma	22/128 (17.2)	29/217 (13.4)	0.334
Dog ownership	40/127(31.5)	80/216(37.0)	0.298
Cat ownership	29/127(22.8)	54/215(25.1)	0.634
Current asthma	20/126 (18.3)	39/213 (18.3)	0.567
Current wheeze	18/126(14.3)	33/215 (15.3)	0.790
	Mean(SD)	Mean(SD)	t-test
Age at follow up	16.0 (0.65)	16.1 (0.55)	0.763
Birth weight (kg)	3.42 (0.47)	3.51(0.91)	0.242

533

534

.

It is made available under a CC-BY-NC-ND 4.0 International license .

535 Table 2: Differences between males and females in IFN and IFN-induced chemokine responses to

- 536 viral stimuli. Data were analysed using the Wilcoxon test. *P* values and adjusted *P* values less than 0.05
- are in bold. The group with the higher IFN and IFN-induced chemokine induction is highlighted in grey.

Stimulus	Cytokine	Median log2 fold Induction [IQR]	Median log2 fold Induction [IQR]	Female to Male ratio in fold induction	<i>P</i> value	Adjusted <i>P</i> value
		Female, n=128 (37.2%)	Male, n=216 (62.8%)			
	IFN-α	10.24 [8.98-11.55]	9.30 [7.88-10.53]	1.92	<0.001	0.001
	IFN-β	6.01 [4.66-7.26]	4.98 [2.02-6.66]	2.04	<0.001	0.003
RV-A16	IFN-γ	7.69 [6.04-8.90]	6.87 [5.03-8.15]	1.77	0.003	0.017
	CCL4/MIP-1β	2.13 [1.47-3.25]	1.98 [0.96-2.98]	1.11	0.125	0.231
	CXCL10/IP-10	4.15 [3.13-5.27]	3.66 [2.36-4.95]	1.04	0.010	0.041
	CCL13/MCP4	2.60 [1.19-3.85]	2.10 [0.93-3.41]	1.41	0.076	0.149
	CCL2/MCP1	2.09 [1.09-2.95]	1.91 [0.95-2.92]	1.13	0.659	0.721
		Female n=128 (37.1%)	Male n=217 (62.9%)			
	IFN-α	11.66 [10.53-12.53]	11.24 [9.91-12.21]	1.34	0.018	0.055
	IFN-β	6.89 [5.83-7.49]	6.62 [5.58-7.71]	1.21	0.583	0.658
RSV	IFN-γ	7.08 [5.88-8.14]	6.54 [4.84-8.11]	1.45	0.062	0.142
	CCL4/MIP-1β	1.60 [1.08-2.36]	1.58 [0.98-2.20]	1.01	0.380	0.475
	CXCL10/IP-10	3.67 [2.59-4.83]	3.36 [2.38-4.62]	1.24	0.210	0.304
	CCL13/MCP4	1.46 [0.42-2.51]	1.12 [-0.11-2.13]	1.27	0.019	0.055
	CCL2/MCP1	1.75 [0.93-2.53]	1.64 [0.64-2.65]	1.08	0.799	0.848
		Female n=115 (37.2%)	Male n=194 (62.8%)			
	IFN-α	7.54 [5.68-8.92]	6.91 [4.92-8.34]	1.55	0.011	0.041
	IFN-β	1.21 [1.21-3.61]	1.21 [1.21-3.16]	1.00	0.483	0.583
RV-A1	IFN-γ	6.08 [4.32-7.27]	5.51 [3.69-6.83]	1.48	0.066	0.142
	CCL4/MIP-1β	0.93 [0.43-1.41]	0.71 [0.20-1.13]	1.16	0.010	0.041
	CXCL10/IP-10	3.05 [1.94-4.17]	2.75 [1.36-3.85]	1.23	0.041	0.104
	CCL13/MCP4	3.39 [2.07-4.47]	2.70 [0.67-3.80]	1.61	0.002	0.017
	CCL2/MCP1	2.00 [1.09-2.77]	1.84 [0.85-2.58]	1.12	0.217	0.304
		Female n=102 (37.6%)	Male n=169 (62.4%)			
	IFN-α	9.91 [8.41-11.52]	8.87 [7.47-10.26]	2.06	<0.001	0.002
	IFN-β	1.53 [1.53-3.27]	1.53 [1.53-2.84]	1.00	0.158	0.261
R848	IFN-γ	7.51 [5.84-9.14]	7.11 [5.45-8.60]	1.32	0.164	0.261
	CCL4/MIP-1β	3.58 [2.94-4.45]	3.46 [2.56-4.42]	1.09	0.375	0.475
	CXCL10/IP-10	2.15 [1.25-3.15]	1.79 [1.04-2.82]	1.28	0.069	0.142
	CCL13/MCP4	0.83 [-0.31-1.85]	0.76 [-0.85-1.69]	1.05	0.239	0.322
	CCL2/MCP1	2.26 [0.79-3.14]	2.02 [0.97-3.04]	1.18	0.914	0.914
		Female n=91 (36.9%)	Male n=156 (63.1%)			
	IFN-α	12.6 [10.99-13.73]	11.83 [10.47-13.38]	1.71	0.015	0.051
	IFN-β	6.31 [2.86-8.10]	5.71 [1.40-7.56]	1.52	0.155	0.261
CpG-A	IFN-γ	4.04 [2.29-5.17]	3.03 [1.54-4.26]	2.01	0.003	0.017
	CCL4/MIP-1β	1.35 [0.91-1.91]	1.43 [0.87-1.81]	0.95	0.857	0.882
	CXCL10/IP-10	4.02 [2.94-4.93]	3.66 [2.71-4.67]	1.28	0.204	0.304
	CCL13/MCP4	2.56 [1.70-3.53]	2.12 [0.88-3.32]	1.36	0.040	0.104
	CCL2/MCP1	1.66 [1.07-2.19]	1.54 [0.89-2.07]	1.09	0.528	0.616